Literature DB >> 6103725

Relationship between the (--)-[3H]-dihydroalprenolol binding to beta-adrenoceptors and transmembrane 86Rb efflux of the BC3H1 nonfusing muscle cell line.

J P Mauger, M Worcel.   

Abstract

1 We have studied the binding properties of the beta-adrenoceptor antagonist [3H]-dihydroalprenolol ([3H]-DHA) on a membrane preparation of the non-fusing muscle cells BC3H1. 2 [3H]-DHA appears to bind to two classes of sites. The first site has a high affinity (KD = 0.53 nM) and a low capcity (Bmax = 58 fmol/mg of protein). The second site has a low affinity (KD = 110 nM) and a high capacity (Bmax = 1100 fmol/mg of protein). 3 The pharmacological properties of the high affinity low capacity site correspond to the known properties of the beta 2-adrenoceptors since the agonists inhibit [3H]-DHA binding following the series isoprenaline greater than adrenaline greater than noradrenaline greater than phenylephrine and the antagonists following the series alprenolol congruent to propranolol greater than butoxamine greater than practolol greater than phentolamine. 4 The binding properties of the beta-adrenoceptors were correlated with the effect of beta-adrenoceptor agonists and antagonists on 86Rb efflux rate from BC3H1 Cells. 5 There is very good correlation between the dissociation constants obtained by inhibition of [3H]-DHA binding by the antagonists alprenolol and propranolol, and the inhibition constants calculated from their antagonism of the 86Rb efflux rate stimulation by adrenaline. The ratio of the dissociation constants obtained by inhibition of [3H]-DHA binding by agonists and their EC50, calculated from 86Rb efflux curves, is higher than 1. This high KD/EC50 ratio indicates a high coupling efficiency between receptor occupancy by agonists and the biological effect measured.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6103725      PMCID: PMC2044234          DOI: 10.1111/j.1476-5381.1980.tb10866.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

Review 1.  In vitro study of beta-adrenergic receptors.

Authors:  B B Wolfe; T K Harden; P B Molinoff
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

2.  Use of (-)-[3H]dihydroalprenolol to study beta adrenergic receptor-adenylate cyclase coupling in C6 glioma cells: role of 5'-guanylylimidodiphosphate.

Authors:  M Lucas; J Bockaert
Journal:  Mol Pharmacol       Date:  1977-03       Impact factor: 4.436

3.  Relationship between the beta-adrenergic receptor and adenylate cyclase.

Authors:  E M Ross; M E Maguire; T W Sturgill; R L Biltonen; A G Gilman
Journal:  J Biol Chem       Date:  1977-08-25       Impact factor: 5.157

4.  Selective blockade of adrenoceptive beta receptors in the heart.

Authors:  D Dunlop; R G Shanks
Journal:  Br J Pharmacol Chemother       Date:  1968-01

Review 5.  The beta-adrenergic receptor and adenylate cyclase.

Authors:  R J Lefkowitz; L E Limbird; C Mukherjee; M G Caron
Journal:  Biochim Biophys Acta       Date:  1976-04-13

6.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

7.  Beta-Adrenergic receptor interactions. Direct comparison of receptor interaction and biological activity.

Authors:  E M Brown; S A Fedak; C J Woodard; G D Aurbach
Journal:  J Biol Chem       Date:  1976-03-10       Impact factor: 5.157

8.  Differentiation of receptor systems activated by sympathomimetic amines.

Authors:  A M Lands; A Arnold; J P McAuliff; F P Luduena; T G Brown
Journal:  Nature       Date:  1967-05-06       Impact factor: 49.962

9.  The adrenergic blocking activity of N-tert.-butylmethoxamine (butoxamine).

Authors:  B Levy
Journal:  J Pharmacol Exp Ther       Date:  1966-03       Impact factor: 4.030

10.  Characterization of a unique muscle cell line.

Authors:  D Schubert; A J Harris; C E Devine; S Heinemann
Journal:  J Cell Biol       Date:  1974-05       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.